Ivonescimab combined with gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer

Key Points

• To evaluate the effectiveness of ivonescimab combined with gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer.
• Phase II trial design
• Evaluation of treatment efficacy in patients with advanced biliary tract cancer
• Combination therapy of ivonescimab, gemcitabine, and cisplatin
• Significant improvement in response rates compared to historical controls
• Reduction in disease progression observed
• Enhanced overall survival noted in the treatment group

Abstract